{"id":"W2953748643","doi":"10.1200/jco.2006.24.18_suppl.533","title":"Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Mount Sinai Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Epirubicin; Breast cancer; Anthracycline; Internal medicine; Cyclophosphamide; Hazard ratio; Chemotherapy; Tissue microarray; Oncology; Cancer; Gynecology; Gastroenterology; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00223724,0.0001436095,0.001315361,0.0001138346,0.00002255833,0.000007120155,0.0001283779,0.0002023988,0.000009185613],"category_scores_gemma":[0.0002487832,0.0001064006,0.000100908,0.0001137865,0.00016078,0.000008688653,0.00008968385,0.0003080422,1.270967e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001239754,"about_ca_system_score_gemma":0.000780026,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003071483,"about_ca_topic_score_gemma":0.0008045782,"domain_scores_codex":[0.9974635,0.0004809028,0.00138832,0.0002318032,0.0001804693,0.0002549588],"domain_scores_gemma":[0.9983948,0.0003648752,0.0007993563,0.00009808251,0.0001962588,0.0001466385],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9600689,0.001355932,0.01102515,0.00001545641,0.0003167724,0.00005121607,0.000311311,0.001543417,0.02002468,0.0001015118,0.00003106345,0.005154551],"study_design_scores_gemma":[0.8231751,0.03302456,0.136613,0.0002775802,0.0002799316,0.0001151698,0.000216501,0.0006346432,0.004030169,0.0007496785,0.0006348024,0.0002488761],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969107,0.0004112321,0.0006102524,0.0008441078,0.0002841199,0.0007319027,0.00002879566,0.000001294974,0.0001775813],"genre_scores_gemma":[0.9980183,0.000272463,0.0006745511,0.0004321401,0.0004757706,0.00007427077,0.000004257063,0.00001367879,0.00003459434],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1368938,"threshold_uncertainty_score":0.4338889,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02351475919426307,"score_gpt":0.3650299615452188,"score_spread":0.3415152023509557,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}